UnitedHealth executive acquires 84 dividend shares

Humana (HUM) shares rose 7% to $406.42 after Barclays upgraded it to Overweight and set a $515 price target. UnitedHealth (UNH) gained 0.7%. Humana's YTD gain is now 60%, driven by analyst sentiment. The move is isolated, with no sector-wide impact.

Florida sued Eli Lilly, Novo Nordisk, and pharmacy benefit managers, alleging they used rebates to maintain high drug prices, harming patients and independent pharmacies. The state claims these practices discouraged competition and limited access to affordable treatments, seeking damages and changes to pricing practices. The case focuses on insulin and GLP-1 medications, with Florida citing significant market power among the defendants.

The Trump administration plans to remove 750,000 ACA enrollees due to alleged fraud, saving $2.2B. Affected individuals include those unaware of enrollments, high earners, and those with employer-provided healthcare. Leading ACA marketplace operators traded lower on the news.

UnitedHealth (UNH) reports Medicare costs below estimates for 2026, but commercial health plan costs are higher than expected. Management attributes commercial cost increases to the federal arbitration process under the No Surprises Act. UNH expects commercial margin recovery to extend past 2027, delaying full margin expansion. The company raised its 2026 adjusted EPS guidance to $19.50-$20 and maintains a 13%-16% long-term growth rate.

UnitedHealth (NYSE:UNH) sold an interest in its Florida-based WellMed clinics to TPG, aiming to improve Optum Health's performance. The division reported a $1.1B operating loss in 2025, with targeted margins of 2%, 4%, and 6% for 2026-2028. The partnership is expected to accelerate growth and operational improvements, though underlying cost pressures remain.

UnitedHealth Group (UNH) shares fell 3% following TPG's acquisition of Florida WellMed Clinics, ahead of guidance reaffirmation. The deal involves Optum clinics that previously impacted UnitedHealth's profits. The company is set to reaffirm its guidance soon, which could validate the deal or raise concerns among investors.